VISIT 1 SCREENING & ENROLLMENT (DAY 0)

DATE OF	VISIT: 8-12-2017 (d	ld/mm/yyyy)		
DATE OF	VISI1: 5-(2-1/0	d/illil/yyyy)		
INFORMI	ED CONSENT:			
	ten informed consent obtained (18 year			
	rmed Consent Obtained: <u>O8 · 12 · 20</u> ten informed assent obtained (age 5-17			
Has audio-vi	deo recording of informed consent pro	cess taken? Yes No NA		
DEMOGR	RAPHIC DETAILS:			
DOB:	0 1 N 0 V 2 0 + 7	08/12/17		
Age : □[6](Years)			
Gender : 🔀	Male Female			
	Hispanic or Latino	Non- Hispanic or Latino		
Ethnicity:	Unknown	Not reported		
	Other, specify			
	White	Native Hawaiian or Other Pacific Islander		
Race:	X Asian	American Indian or Alaska Native		
	Black or African American	Other, specify		
Recorded B	y (sign and date):	117		



Subject Screening No.: 5000 | Subject Initial: ABV

MED	ICAL/SURGICAL HISTORY:			
⊠ No	one (please Check the box if the subject	doesn't have any Medica	l /Surgical history)	
	Subject taking any medication for ongo s please fill concomitant medication page		Yes No	
Sr. No.	Medical / Surgical history	Start date (DD-MMM-YYYY)	Stop date (DD-MMM-YYYY)	Ongoing
1				
2				
3				
4				
5	- 14		4	



Sr. No.	Trade/ Generic Name	Route Code only	Frequency Code only	Indication	Start date	Stop Date	Ongoin
-							
			, , , , , , , , , , , , , , , , , , , ,		,		
	/						

8/12/1×



Frequency: 1=Once Daily, 2=Twice Daily, 3=Thrice Daily, 4=Four Times Daily, 5=As and When Required

Subject Screening No.: SPKO | Subject Initial: ABV

Was the physical examination p	erformed?			ĭ Yes	□No
If No, Specify Reason:					_
If Yes, Date of Assessment			0 8	- NOV -	2017
				Result	
Physical Examination	*Not Done	Normal	Abnormal	If Abnormal (check one)	If Abnormal CS, please describe the abnormality
General Appearance		d		□CS □NCS	
Cardiovascular System		V		□CS □NCS	
Respiratory System		Ø		□CS □NCS	
Gastrointestinal System		Ø		□CS □NCS	
Musculoskeletal System				□CS □NCS	
Central Nervous System				□CS □NCS	
Reproductive System		. 🗹		□CS □NCS	
Other	Ø			□cs □ncs	
Other system (Except Not I	Done)				
Performed by (Name):	n P	H- (to	exui		



Subject Screening No.: Spx 00 | Subject Initial: ABV

VITAL SIGN	IS:				
, Was the vital signs collected?				✓Yes 🗀	No.
Date of Assessment			08-	D & 4 - 2	
Height (cm):	66.0	Weight (kg): 0月恩. 0	BMI (kg/m2	
Parameters	Result	Normal	Abnormal	If Abnormal (check one)	If Abnormal CS, please describe the abnormality
Systolic Blood Pressure	136mmHg			□CS□NCS	
Diastolic Blood Pressure	036mmHg			□CS □NCS	
Pulse rate	四子图 beats/min	×		□cs □ncs	
Oral Temperature	093.9°F	赵		CS NCS	
Respiratory rate	DU9 breaths/min	赵		□cs □ncs	
Recorded By (Sig	gn and date): Vis	heiling	8/12/	14_	
ECG DETAIL	S:				
Was ECG perform	ned? ⊠Yes □ No			The second secon	
Date of ECG Assessment 0 8 0 6 0 - 2 0 1 7			Time of ECG	Assessment 0 4 (24 hours form	nat)
Result?			Normal Normal	Abnormal	
If Abnorma	If Abnormal, Clinically significant?			□No	
If Yes*, please spe	cify		Par les III		
Recorded By (Sign	n and date):	AM .	2HX		



Subject Screening No.: 501600 | Subject Initial: ASV

ALCOHOL HISTORY:	
Usage: ☐Past History ☐*Reg	gular Occasional Never
If *Regular please specify:	Unit/day
Has subject agreed to follow ale	cohol restriction as per protocol? Yes No
Recorded By (Sign and date):	20012119
URINE PREGNANCY TEST	
Pregnancy test performed?	Yes No Not Applicable (Male)
If yes, Date of Pregnancy test	D::D:(DD-MMM-YYYY)
Result	Positive Negative
If No specify reason	Post-Menopausal Surgically Sterile
If Postmenopausal since	D::D::D::D::DD-MMM-YYYY)
Recorded by (Sign and date):	A 08/12/19
CONTRACEPTIV MET	HOD:
Contraceptive method used	
If Yes, describe the method	Male confeareption (Using of Condom)
	0019(01:)

6/12/17



Subject Screening No.: SPK ON | Subject Initial: ABV

LABORATORY ASSESSMENT					
Date of blood sample collection:	Time: []: 70				
Date of urine sample collection:	3-500-2009	Time: 11:115			
Overall Assessment	☐ Normal ☒ Abnormal NCS ☐ Abn	normal CS			
Sample Repeated	Yes No				
If Yes, Date of repeat sample collection	DD:DD:DD:DD-MMM	-YYYY)			
If Yes, Time of repeat sample collection	□□:□□ (HH:MM)				
If Yes, Panel repeated	Hematology Biochemistry Immunology	Urinalysis			
If Yes, Overall Assessment	f Yes, Overall Assessment				
Recorded by(Sign and Date):	11211)				
IMMUNOGENICITY ASSES	SSMENT:				
Date of sample Collection	8-2101-2017				
Comments if, any:					
DIDI					
RVNA ASSESSMENT:					
Date of sample Collection	8-00-2017				
Comments if, any:					



INC	INCLUSION CRITERIA:				
Sr. No.	Criteria	Yes	No		
1.	Male and Female patient aged 5 years or more than 5 years.	X			
2.	WHO Category III exposure(s) by a suspected rabid animal.				
3.	Have documented informed consent from individuals, the child's parent(s) or legal guardian(s) and assent from the child if appropriate.				
4.	Free of obvious health problems as determined by history and examination.				
5.	If female, not pregnant or lactating at the time of enrolment and not planning pregnancy during the vaccination period.				
6.	Male subject must be agree to use at least one effective contraceptive method through out the entire duration of the study.				
		The second second second second			

EXC	LUSION CRITERIA:		
SR. No.	Criteria	Yes	No
1.	Pregnant and lactating women.		NA 🗆
2.	Patient has received any dose of rabies vaccines / rabies immunoglobulin in the past.		Q
3.	Allergic to any of the vaccine component / human rabies immunoglobulin components.		
4.	Chronic administration of immune suppressants or other immune-modifying agents.		
5.	Unable to follow all required study procedures for the whole period of the study.		
6.	Acute febrile illness or acute infectious disease.		[X]
7.	Acute or chronic, clinically significant pulmonary, endocrine, autoimmune, psychiatric, cardiovascular, hepatic or renal functional abnormality, which in the opinion of the investigator might interfere with the study objectives.		
8.	History of a previous severe allergic reaction.		

Subject Screening No.: 504001

Subject Initial: ABV

9. History of thrombocytopenia or known bleeding disorders.	History of thrombocytopenia or known bleeding disorders.				
History or current use of drugs of abuse or heavy alcohol Consumption.					
11. Received any other vaccines within 3 month prior to enrollment.	Ø				
12. History of serious and / or severe infections such as Hepatitis C virus (HCV), hepatitis Bvirus (HBV) infections, tuberculosis.					
Simultaneous participation in other clinical trials, previous participation in other clinical trials within 3 months before entering into the trial.					
14. History of untreated dog bites.	区				
If Subject has received exceptions/waivers, please provide description or waiver or any Comment					
INCLUSION/EXCLUSION CRITERIA REVIEW Has the Subject Eligible for randomization? Yes No					
If No, please specify the inclusion / exclusion criteria numbers that were not met					
Inclusion Criteria number					
Exclusion criteria number					
If Subject has received					
exceptions/waivers, please provide					
description or waiver or any					
RANDOMIZATION:					
Was the subject Randomized as per randomization plan? ☐ Yes ☐ No					
If *Yes, provide the Date of Randomization:					
Subject number assigned: E P K - V D J					
Kit number: Coll					
Treatment Arm ∑A: RABIMABs + Vaxirab N					
☐B: Rabies Immuno globulin (Imogam®) + Vaxirab N					

Subject Screening No.: Sproof Subject Initial: ABV

IMP ADMINISTRATION	
Date of study drug administration:	08-964-2017
Time of study drug administration:	11 1 : 2 0
Treatment Administered	☐ RABIMABs + Vaxirab N ☐ B: Rabies Immunoglobulin (Imogam®) +Vaxirab N
Total study drug administered?	
Was Study drug administered directly in the surround area of the wounds by dog bite?	10.4 ml 10 ml of reasionals was told from vial 1 and 0.4 ml taken from vial 2.
Was Study drug administered intramuscularly in different part of the body?	ĭXYes*□No
If Yes*, select site(s) of injection	□ Left Deltoid □ Right Deltoid □ Left Gluteal □ Right Gluteal □ Left Anterolateral thigh □ Right Anterolateral thigh
Site of deltoid muscle (Vaxirab N)	☐
Subject kept under observation up to 30 minutes after administration of assigned treatment.	⊠Yes □No
Recorded by (sign and date):	08/12/19
LOCAL AND SYSTEMIC REACTI	ION
Has subject experienced any Local or Systemic reaction?]Yes*⊠No
f Yes*, please specify	Indurations Redness Pain Fever Swelling Others
Comments (If Other, specify):	ALL SILVE

Sty HOSE IT OF

Subject Screening No.: Spx 00 | Subject Initial: ABV

ADVERSE EVENT AND/ CONCOMIT.	ANT MEDIACTION ASSESSMENT
Has the subject experienced any new adverse event in this visit?	☐Yes ☑No
Has the subject taken any new medication in this visit?	□Yes ☑No
Comments: 0.4 ml extere fabrimal extere bulk of pu Lab samples for sajety processed as per prot	Les avas terren ferom Lorided lucing snipmy Lord RVNA has been cool requirement. AND ROLL AND AND ROLL AND
PI or/ Designee Sign and Date:	= 8/11/17 AITINE

